Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label, multicenter, single-arm study

BACKGROUND: Neoadjuvant therapy has significantly improved the 5-year overall survival (OS) of patients with resectable non-small cell lung cancer (NSCLC). The CheckMate 159 trial showed that neoadjuvant therapy with a single-drug programmed cell death protein 1 (PD-1) inhibitor (nivolumab) achieved...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Hongtao, Wang, Tianhu, Luo, Zhilin, Tong, Liping, Dong, Xiaoping, Zhang, Yong, Afzal, Muhammad Zubair, Correale, Pierpaolo, Liu, Honggang, Jiang, Tao, Yan, Xiaolong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947385/
https://www.ncbi.nlm.nih.gov/pubmed/33718040
http://dx.doi.org/10.21037/tlcr-21-130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947385/
https://www.ncbi.nlm.nih.gov/pubmed/33718040
http://dx.doi.org/10.21037/tlcr-21-130

Ejemplares similares